NCT02478788View on ClinicalTrials.gov

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

PHASE4CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2022

Study Completion Date

December 31, 2022

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

mixed amphetamine salts-extended release (MAS-XR)

MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.

DRUG

Placebo

Pills with no medication in it

Trial Locations (1)

45219

University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati

All Listed Sponsors

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Cincinnati

OTHER

NCT02478788 - Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder | Biotech Hunter | Biotech Hunter